Gilead’s weekly HIV pill has passed Phase 3, but can fewer doses deliver better treatment adherence?
Gilead Sciences will present research spanning HIV prevention, treatment and early cure strategies at HIV Glasgow 2026. The programme includes new analyses of an already successful once-weekly Phase 3 regimen, real-world treatment evidence and investigations into twice-yearly injections, with several important regulatory and clinical questions still unresolved.